Morgan Stanley Issues Positive Forecast for Envista (NYSE:NVST) Stock Price

Envista (NYSE:NVST) had its price objective hoisted by research analysts at Morgan Stanley from $19.00 to $20.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target suggests a potential downside of 2.82% from the company’s current price.

NVST has been the subject of a number of other research reports. Stifel Nicolaus raised their target price on shares of Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Jefferies Financial Group raised their price objective on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Leerink Partners raised Envista from an “underperform” rating to a “market perform” rating and increased their price target for the company from $16.00 to $23.00 in a research report on Thursday, October 31st. Leerink Partnrs raised Envista from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 31st. Finally, Piper Sandler increased their price objective on Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Monday. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $20.13.

Envista Stock Performance

NVST opened at $20.58 on Thursday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -2.65, a P/E/G ratio of 1.82 and a beta of 1.34. The business’s 50-day moving average price is $19.97 and its two-hundred day moving average price is $19.10. Envista has a 1 year low of $15.15 and a 1 year high of $24.79.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. Equities analysts expect that Envista will post 0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

Several large investors have recently modified their holdings of NVST. Mirae Asset Global Investments Co. Ltd. bought a new position in Envista in the 3rd quarter valued at about $31,000. GAMMA Investing LLC boosted its stake in Envista by 69.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after purchasing an additional 726 shares during the period. Huntington National Bank increased its position in Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after buying an additional 949 shares during the period. Venturi Wealth Management LLC lifted its holdings in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after buying an additional 1,638 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.